{"schema_version":"secwatch.filing_event.v1","accession":"0001388658-22-000126","form_type":"8-K","ticker":"IRTC","cik":"0001388658","company_name":"iRhythm Holdings, Inc.","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.582961+00:00","generated_at":"2026-06-24T03:15:11.963995+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iRhythm Q2 revenue $102.1M (+26% YoY), raises FY22 guidance to $415-420M, loss widens","bullets":["Revenue $102.1M (+25.6% YoY); gross margin 68.8% (up 0.8pp).","Net loss $23.9M ($0.80 loss per share) vs $17.4M loss in Q2 2021.","FY22 revenue guidance raised to $415-420M (29-30% growth); adj. EBITDA loss guidance $(12.5)-$(17.5)M.","Cash $204.5M; record new account openings (+22% QoQ) and sequential revenue volume growth of 10%.","FDA 510(k) cleared Zio Watch (Verily partnership); CMS proposed reimbursement for Zio XT CPT codes."],"urls":{"canonical":"https://secwatch.observer/filing/0001388658-22-000126","json":"https://secwatch.observer/filing/0001388658-22-000126.json","markdown":"https://secwatch.observer/filing/0001388658-22-000126.md","text":"https://secwatch.observer/filing/0001388658-22-000126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388658/000138865822000126/0001388658-22-000126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388658/000138865822000126/irtc-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:15:11.963995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}